Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)46.83
  • Today's Change-3.45 / -6.86%
  • Shares traded13.56m
  • 1 Year change-34.36%
  • Beta1.6111
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. Its diverse development pipeline consists of 45 therapeutic and vaccine programs, nine of which are in late-stage development. Its products include COVID-19 vaccines (mRNA-1273/Spikevax, next-generation mRNA-1283), RSV vaccine (mRNA-1345), Seasonal influenza vaccines (mRNA-1010, mRNA-1011, mRNA-1012, mRNA-1020 and mRNA-1030), Combination vaccines (mRNA-1083, mRNA-1230, mRNA-1045 and mRNA-1365), CMV vaccine (mRNA-1647), EBV vaccine (mRNA-1189 and mRNA-1195) and others.

  • Revenue in USD (TTM)5.08bn
  • Net income in USD-2.22bn
  • Incorporated2016
  • Employees5.60k
  • Location
    Moderna Inc325 BINNEY STREETCambridge 02142United StatesUSA
  • Phone+1 (617) 714-6500
  • Fax+1 (617) 583-1998
  • Websitehttps://www.modernatx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Revolution Medicines Inc742.00k-567.06m10.17bn490.00--6.47--13,702.40-3.59-3.590.00479.340.0005--4.801,962.96-41.28-29.76-44.46-32.59-----76,423.31-606.93----0.00---67.27-10.50-75.46--38.82--
Exelixis Inc2.08bn466.92m10.35bn1.31k23.104.5520.934.971.571.576.927.960.70123.398.041,589,006.0015.738.8618.089.9196.2596.3022.4315.433.88--0.000.0013.6016.4713.98-21.343.98--
Charles River Lbrtrs ntrntl Inc4.06bn413.08m11.01bn20.00k26.892.9114.342.718.018.0178.6373.970.52038.275.23203,045.805.486.466.337.6235.9336.9910.5411.581.144.960.37840.003.8612.75-2.3916.6917.86--
Medpace Holdings Inc2.07bn365.57m11.28bn5.90k31.7712.7628.595.4511.4211.4264.7028.421.16--6.85350,994.3020.4813.9443.5123.1829.6928.8417.6615.23----0.00--29.1721.7615.2631.1717.99--
Tempus AI Inc640.44m-800.71m11.38bn2.30k--213.26--17.78-8.29-8.294.440.3459----------------53.18---116.06--2.55-14.950.891--65.85--20.35------
Sarepta Therapeutics Inc1.64bn121.85m11.62bn1.31k100.009.5172.387.081.221.2216.3012.790.4890.57034.351,248,362.003.63-21.634.38-25.7585.9286.657.43-77.053.03--0.5013--33.2632.8023.81--6.30--
BIO-TECHNE Corp1.17bn150.68m12.07bn3.10k80.805.6446.0610.300.94020.94027.2913.460.42672.155.47377,930.005.499.425.7710.0465.9367.2912.8621.413.2618.070.12322.791.9710.17-41.0711.8619.870.00
Neurocrine Biosciences, Inc.2.24bn385.90m12.73bn1.70k33.674.6830.935.683.733.7321.6726.870.70270.89014.991,602,000.0012.099.7714.6712.1998.5298.5117.2114.794.2610.280.00--26.7633.1361.6263.902.67--
Insmed Inc342.96m-864.29m13.16bn912.00--27.21--38.36-5.56-5.562.212.700.20310.88488.81376,050.40-51.17-40.96-59.16-46.8877.2577.99-252.01-212.925.99-18.410.6702--24.3998.78-55.66---2.15--
Vaxcyte Inc0.00-507.65m13.29bn254.00--3.88-----4.55-4.550.0027.470.00----0.00-20.08-34.22-20.95-37.21------------0.00-------80.00--107.28--
Summit Therapeutics Inc0.00-196.68m15.79bn105.00--36.04-----0.2768-0.27680.000.59410.00----0.00-54.53-77.32-71.71-86.35-------20,989.46----0.053---100.00---680.54---4.84--
ICON PLC8.31bn747.89m17.74bn42.25k23.901.8213.762.148.998.9999.87118.390.4852--2.99202,112.504.373.935.244.8029.6328.919.007.37--4.410.2599--4.8925.6221.1813.6723.79--
Moderna Inc5.08bn-2.22bn18.00bn5.60k--1.51--3.54-5.81-5.8113.1430.980.28832.442.96907,321.40-12.6220.95-15.5229.5178.43---43.7732.104.20--0.05210.00-64.45119.28-156.37--46.22--
United Therapeutics Corporation2.76bn1.11bn18.30bn1.17k18.023.0015.556.6422.7522.7556.36136.740.38972.439.182,359,760.0015.7110.3817.7311.2788.9491.4740.3129.254.41--0.06150.0020.207.4135.4010.894.55--
Data as of Nov 08 2024. Currency figures normalised to Moderna Inc's reporting currency: US Dollar USD

Institutional shareholders

41.19%Per cent of shares held by top holders
HolderShares% Held
Baillie Gifford & Co.as of 30 Sep 202442.46m11.05%
The Vanguard Group, Inc.as of 30 Jun 202438.14m9.92%
Fidelity Management & Research Co. LLCas of 30 Jun 202420.17m5.25%
BlackRock Fund Advisorsas of 30 Jun 202417.14m4.46%
SSgA Funds Management, Inc.as of 30 Jun 202415.02m3.91%
Th�l�me Partners LLPas of 30 Jun 20247.23m1.88%
Geode Capital Management LLCas of 30 Jun 20246.89m1.79%
Wellington Management Co. LLPas of 30 Jun 20244.26m1.11%
Capital Research & Management Co. (World Investors)as of 30 Jun 20243.67m0.95%
Norges Bank Investment Managementas of 30 Jun 20243.35m0.87%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.